Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 13.55
CPIX's Cash-to-Debt is ranked higher than
63% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. CPIX: 13.55 )
Ranked among companies with meaningful Cash-to-Debt only.
CPIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.16  Med: 13.48 Max: No Debt
Current: 13.55
Equity-to-Asset 0.82
CPIX's Equity-to-Asset is ranked higher than
81% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. CPIX: 0.82 )
Ranked among companies with meaningful Equity-to-Asset only.
CPIX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.85 Max: 0.91
Current: 0.82
0.42
0.91
Piotroski F-Score: 4
Altman Z-Score: 4.72
Beneish M-Score: -2.41
WACC vs ROIC
7.60%
-0.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -0.98
CPIX's Operating Margin % is ranked lower than
75% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. CPIX: -0.98 )
Ranked among companies with meaningful Operating Margin % only.
CPIX' s Operating Margin % Range Over the Past 10 Years
Min: -11.87  Med: 13.72 Max: 23.96
Current: -0.98
-11.87
23.96
Net Margin % -0.14
CPIX's Net Margin % is ranked lower than
73% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. CPIX: -0.14 )
Ranked among companies with meaningful Net Margin % only.
CPIX' s Net Margin % Range Over the Past 10 Years
Min: -6.57  Med: 9.08 Max: 24.72
Current: -0.14
-6.57
24.72
ROE % -0.06
CPIX's ROE % is ranked lower than
69% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. CPIX: -0.06 )
Ranked among companies with meaningful ROE % only.
CPIX' s ROE % Range Over the Past 10 Years
Min: -2.55  Med: 6.91 Max: 50.74
Current: -0.06
-2.55
50.74
ROA % -0.05
CPIX's ROA % is ranked lower than
67% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. CPIX: -0.05 )
Ranked among companies with meaningful ROA % only.
CPIX' s ROA % Range Over the Past 10 Years
Min: -2.26  Med: 5.3 Max: 24.03
Current: -0.05
-2.26
24.03
ROC (Joel Greenblatt) % -3.03
CPIX's ROC (Joel Greenblatt) % is ranked lower than
71% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. CPIX: -3.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CPIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -43.4  Med: 92.21 Max: 1721.07
Current: -3.03
-43.4
1721.07
3-Year Revenue Growth Rate -7.40
CPIX's 3-Year Revenue Growth Rate is ranked lower than
80% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. CPIX: -7.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CPIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.4  Med: 3.25 Max: 47.3
Current: -7.4
-7.4
47.3
3-Year EBITDA Growth Rate -25.60
CPIX's 3-Year EBITDA Growth Rate is ranked lower than
91% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. CPIX: -25.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CPIX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -25.6  Med: 2.5 Max: 109
Current: -25.6
-25.6
109
3-Year EPS without NRI Growth Rate -48.90
CPIX's 3-Year EPS without NRI Growth Rate is ranked lower than
95% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. CPIX: -48.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CPIX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: -14.3 Max: 34.2
Current: -48.9
-48.9
34.2
GuruFocus has detected 4 Warning Signs with Cumberland Pharmaceuticals Inc $CPIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CPIX's 10-Y Financials

Financials (Next Earnings Date: 2017-03-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CPIX Guru Trades in Q1 2016

John Rogers 1,976,671 sh (+39.53%)
Jim Simons 222,600 sh (+2.49%)
» More
Q2 2016

CPIX Guru Trades in Q2 2016

Jim Simons 235,300 sh (+5.71%)
John Rogers 1,992,613 sh (+0.81%)
» More
Q3 2016

CPIX Guru Trades in Q3 2016

Jim Simons 247,100 sh (+5.01%)
John Rogers 2,049,760 sh (+2.87%)
» More
Q4 2016

CPIX Guru Trades in Q4 2016

Jim Simons 257,000 sh (+4.01%)
John Rogers 1,824,580 sh (-10.99%)
» More
» Details

Insider Trades

Latest Guru Trades with CPIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:CPHRF, NAS:NEOS, NAS:BPTH, NAS:CPRX, NAS:SCYX, OTCPK:ZOMHF, NAS:MSLI, NAS:SPHS, NAS:TYHT, NAS:ADMP, NAS:AGRX, NAS:LPCN, NAS:EPIX, NAS:STDY, NAS:MEIP, NAS:OREX, NAS:PSDV, OTCPK:MGWFF, OTCPK:OWCP, OTCPK:NRIFF » details
Traded in other countries:CBJ.Germany,
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the acquisition, development and commercialization of branded prescription products. Its target markets are hospital acute care and gastroenterology.

Cumberland Pharmaceuticals Inc., was incorporated in Tennessee on January 6, 1999. It is a specialty pharmaceutical company which is engaged in the acquisition, development and commercialization of branded prescription products. It operates in a single operating segment of specialty pharmaceuticals products. Its product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose (lactulose) for Oral Solution, a prescription laxative, and Hepatoren (ifetroban) injection, a Phase II candidate for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS). The Company's target markets are hospital acute care and gastroenterology, which are characterized by concentrated physician bases that it believe can be penetrated effectively by relatively small, targeted sales forces. The Company markets and sells its products through its dedicated hospital and gastroenterology sales forces in the United States, which together comprised more than 65 sales representatives and managers as of March 1, 2013. Acetadote is an intravenous formulation of N-acetylcysteine, or NAC, indicated for the treatment of acetaminophen poisoning. Caldolor, its intravenous formulation of ibuprofen, was the first injectable product approved in the United States for the treatment of both pain and fever. Kristalose is a prescription laxative administered orally for the treatment of constipation. Hepatoren is in Phase II clinical development. Pharmaceutical companies are subject to extensive regulation by national, state, and local agencies in the U.S. and additional regulations in other countries in which do business. It promotes Acetadote and Caldolor through its dedicated hospital sales team and currently utilize two distinct sales teams to address its primary target markets: a hospital sales force for the acute care market and a field sales force for the gastroenterology market. It competes with the product attributes such as efficacy, safety, ease-of-use and cost-effectiveness.

Ratios

vs
industry
vs
history
PB Ratio 1.25
CPIX's PB Ratio is ranked higher than
83% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. CPIX: 1.25 )
Ranked among companies with meaningful PB Ratio only.
CPIX' s PB Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.28 Max: 4.83
Current: 1.25
0.9
4.83
PS Ratio 2.91
CPIX's PS Ratio is ranked higher than
52% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. CPIX: 2.91 )
Ranked among companies with meaningful PS Ratio only.
CPIX' s PS Ratio Range Over the Past 10 Years
Min: 1.66  Med: 2.61 Max: 6.8
Current: 2.91
1.66
6.8
Price-to-Operating-Cash-Flow 91.29
CPIX's Price-to-Operating-Cash-Flow is ranked lower than
91% of the 295 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.98 vs. CPIX: 91.29 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CPIX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.4  Med: 20.73 Max: 1583.33
Current: 91.29
11.4
1583.33
EV-to-EBITDA 20.19
CPIX's EV-to-EBITDA is ranked lower than
60% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.72 vs. CPIX: 20.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
CPIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -56.6  Med: 8.6 Max: 35.6
Current: 20.19
-56.6
35.6
Shiller PE Ratio 30.20
CPIX's Shiller PE Ratio is ranked higher than
68% of the 158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 47.37 vs. CPIX: 30.20 )
Ranked among companies with meaningful Shiller PE Ratio only.
CPIX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 21.7  Med: 26.01 Max: 33.32
Current: 30.2
21.7
33.32
Current Ratio 5.73
CPIX's Current Ratio is ranked higher than
80% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. CPIX: 5.73 )
Ranked among companies with meaningful Current Ratio only.
CPIX' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 5.8 Max: 14.46
Current: 5.73
1.45
14.46
Quick Ratio 5.30
CPIX's Quick Ratio is ranked higher than
81% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. CPIX: 5.30 )
Ranked among companies with meaningful Quick Ratio only.
CPIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.38  Med: 5.36 Max: 13.46
Current: 5.3
1.38
13.46
Days Inventory 275.87
CPIX's Days Inventory is ranked lower than
91% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. CPIX: 275.87 )
Ranked among companies with meaningful Days Inventory only.
CPIX' s Days Inventory Range Over the Past 10 Years
Min: 92.58  Med: 381.63 Max: 636.33
Current: 275.87
92.58
636.33
Days Sales Outstanding 76.15
CPIX's Days Sales Outstanding is ranked higher than
50% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. CPIX: 76.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.88  Med: 51.09 Max: 104.9
Current: 76.15
30.88
104.9
Days Payable 408.98
CPIX's Days Payable is ranked higher than
97% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. CPIX: 408.98 )
Ranked among companies with meaningful Days Payable only.
CPIX' s Days Payable Range Over the Past 10 Years
Min: 103.04  Med: 225.25 Max: 513.19
Current: 408.98
103.04
513.19

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 4.70
CPIX's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. CPIX: 4.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CPIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7  Med: 0.6 Max: 5.1
Current: 4.7
-7
5.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.73
CPIX's Price-to-Net-Cash is ranked higher than
87% of the 250 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.84 vs. CPIX: 2.73 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CPIX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.37  Med: 2.18 Max: 6.72
Current: 2.73
1.37
6.72
Price-to-Net-Current-Asset-Value 1.82
CPIX's Price-to-Net-Current-Asset-Value is ranked higher than
93% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CPIX: 1.82 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CPIX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.07  Med: 1.65 Max: 5.38
Current: 1.82
1.07
5.38
Price-to-Tangible-Book 1.72
CPIX's Price-to-Tangible-Book is ranked higher than
76% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. CPIX: 1.72 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CPIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.04  Med: 1.58 Max: 5.21
Current: 1.72
1.04
5.21
Price-to-Intrinsic-Value-Projected-FCF 1.24
CPIX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. CPIX: 1.24 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CPIX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.73  Med: 1.1 Max: 1.59
Current: 1.24
0.73
1.59
Price-to-Median-PS-Value 1.12
CPIX's Price-to-Median-PS-Value is ranked lower than
51% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. CPIX: 1.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CPIX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.66  Med: 1.04 Max: 2.49
Current: 1.12
0.66
2.49
Earnings Yield (Greenblatt) % -0.33
CPIX's Earnings Yield (Greenblatt) % is ranked lower than
69% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. CPIX: -0.33 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CPIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.33  Med: 7.7 Max: 79.2
Current: -0.33
-0.33
79.2
Forward Rate of Return (Yacktman) % -0.79
CPIX's Forward Rate of Return (Yacktman) % is ranked lower than
68% of the 358 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.67 vs. CPIX: -0.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CPIX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.79  Med: 3.6 Max: 18
Current: -0.79
-0.79
18

More Statistics

Revenue (TTM) (Mil) $31.98
Beta0.69
Short Percentage of Float0.67%
52-Week Range $4.20 - 6.73
Shares Outstanding (Mil)16.18
» More Articles for CPIX

Headlines

Articles On GuruFocus.com
Micro Cap Value Discovery Jul 05 2016 
Speculative Options Buys Apr 29 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 15 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 16 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) May 17 2010 

More From Other Websites
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events Feb 10 2017
Caldolor® Pediatric Fever Study Published Supporting Its Efficacy, Safety And Pharmacokinetics Feb 07 2017
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events Feb 03 2017
U.S. Court Of Appeals Affirms Cumberland Pharmaceuticals' Victory In Patent Litigation Case Jan 30 2017
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 20 2017
Cumberland Pharmaceuticals Announces Kenneth J. Krogulski To Join Its Board Of Directors Jan 16 2017
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jan 13 2017
Cumberland Pharmaceuticals and Clinigen Enter Exclusive U.S. Commercialization Agreement For... Jan 09 2017
Cumberland Emerging Technologies Appoints New Senior Executive Jan 04 2017
ETFs with exposure to Cumberland Pharmaceuticals, Inc. : December 21, 2016 Dec 21 2016
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events Nov 21 2016
Blog Coverage Cumberland Pharma Bags Exclusive Rights for Europe Based Nordic Group Injectable... Nov 17 2016
Cumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group's Methotrexate Injection Products Nov 16 2016
Cumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group's Methotrexate Injection Products Nov 16 2016
CUMBERLAND PHARMACEUTICALS INC Financials Nov 10 2016
Cumberland Pharmaceuticals Presentation Now Available for On-Demand Viewing Nov 07 2016
Cumberland Pharmaceuticals Presentation Now Available for On-Demand Viewing Nov 07 2016
ETF’s with exposure to Cumberland Pharmaceuticals, Inc. : November 4, 2016 Nov 04 2016
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 03 2016
Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3,... Nov 03 2016
Edited Transcript of CPIX earnings conference call or presentation 1-Nov-16 8:30pm GMT Nov 02 2016
Cumberland Pharmaceuticals Reports Third Quarter & Year To Date 2016 Financial Results Nov 01 2016
Cumberland Pharmaceuticals Reports Third Quarter & Year To Date 2016 Financial Results Nov 01 2016
Public Company Executives to Present Online to Investors on November 3 Oct 31 2016
Public Company Executives to Present Online to Investors on November 3 Oct 31 2016
Cumberland Pharmaceuticals To Announce Third Quarter 2016 Financial Results Oct 25 2016
Cumberland Pharmaceuticals Launches Promotion Of Ethyol® In The United States For Oncology Patient... Sep 26 2016
Clinigen Group and Cumberland Pharmaceuticals launch Ethyol® in the U.S. Sep 26 2016
Cumberland Pharmaceuticals Announces New Program To Develop Portaban™ For Portal Hypertension Sep 14 2016
Cumberland Pharmaceuticals Begins U.S. Shipments Of Ethyol® (amifostine) For Oncology Patient... Aug 23 2016
Cumberland Pharmaceuticals Reports Second Quarter 2016 Financial Results Aug 02 2016
Cumberland Pharmaceuticals To Announce Second Quarter 2016 Financial Results Jul 26 2016
Cumberland Pharmaceuticals Announces Caroline Young To Join Its Board Of Directors Jun 10 2016
Cumberland Pharmaceuticals Reports First Quarter 2016 Financial Results May 10 2016
Clinigen Group and Cumberland Pharmaceuticals enter into exclusive U.S. commercialisation agreement... May 10 2016
Cumberland Pharmaceuticals and Clinigen Group enter into exclusive U.S. commercialization agreement... May 10 2016
Cumberland Pharmaceuticals To Announce First Quarter 2016 Financial Results May 03 2016
Cumberland Pharmaceuticals Announces New Program To Develop Vasculan™ For Systemic Sclerosis Apr 27 2016
Caldolor® Launched For The Treatment Of Pain And Fever In Children Mar 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)